Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4736590 | 0.83 | CYP2C19 (0.37) | CYP2C19DRD1ATRRETCYP4F2 | |
| SCHEMBL4752520 | 0.75 | CYP2C19 (0.40) | CYP2C19DRD1ATRRETTP53 | |
| SCHEMBL4736667 | 0.74 | PNP (0.34) | CYP2C19DRD1CYP4F2CYP4A11 | |
| SCHEMBL12715593 | 0.74 | PNP (0.34) | CYP2C19DRD1CYP4F2CYP4A11 | |
| SCHEMBL4751248 | 0.74 | PDCD1 (0.38) | CYP2C19DRD1ATR | |
| SCHEMBL13726338 | 0.71 | DRD1 (0.31) | DRD1ATR | |
| SCHEMBL13726343 | 0.71 | ATR (0.32) | DRD1ATR | |
| SCHEMBL25291226 | 0.69 | CYP2C19 (0.36) | CYP2C19ATRRETCYP4F2CYP4A11 | |
| SCHEMBL23217072 | 0.67 | CYP2C19 (0.43) | CYP2C19ATRRETCYP4F2CYP4A11 | |
| SCHEMBL31206696 | 0.65 | GAA (0.34) | CYP2C19ATRRETCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| US-8173662-B2 | Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2012-05-08 | — | — | US | disclosed |
| EP-1539783-B1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | EINSTEIN COLL MED (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | BIOCRYST PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
| US-7553839-B2 | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-06-30 | — | — | US | disclosed |
| US-7098334-B2 | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-08-29 | — | — | US | disclosed |
| EP-1490373-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-12-29 | — | — | EP | disclosed |
| US-20040110772-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2004-06-10 | — | — | US | disclosed |
| WO-2003080620-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239885-A1 | Inhibitors of nucleoside phoshorylases and nucleosidases | PNP, MTAP, TYMP | CYP2C19 2357/4885DRD1 4651/4885ATR 2439/4885 |
| US-20040110772-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | PNP, RNASEL, TYMP | CYP2C19 2287/4885DRD1 1786/4885ATR 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.